NTLANTLA
US • —
$16.92
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+45.0% YoY
Gross Margin
—
Health Score
5/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Intellia Therapeutics (NTLA) is a biotechnology company focused on developing CRISPR-based gene editing therapies for a range of diseases, primarily using its in vivo delivery platform. The company operates in the highly competitive and innovative gene editing space, positioning itself as a potential leader in in vivo (inside the body) CRISPR therapies, which differentiates it from many peers that rely on ex vivo (outside the body) approaches. With a market capitalisation that is not provided and no publicly available TTM revenue figure, the company is likely a pre-commercial or early-stage biotech. A defining characteristic is its technology platform, which aims to permanently edit disease-causing genes directly within a patient's cells, potentially offering curative therapies for genetic disorders.
Financial Health
A key strength is the balance sheet, with a debt/equity ratio of 0.0x and a current ratio of 5.08x, indicating a fortress-like liquidity position and no reliance on debt financing. However, the return on equity (ROE) is deeply negative at -57.3%, reflecting significant net losses relative to shareholder equity, which is common for a clinical-stage biotech...
Risk Assessment
EARNINGS QUALITY — While the company has beaten earnings estimates in 4/4 recent quarters, this is not a measure of operational profitability; the underlying business is still generating net losses at a high rate. TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. DEBT / LIQUIDITY — The debt/equity ratio is 0.0x, which is exceptionally low and helpful, but it may reflect an inability to access debt markets rather than a conscious choice, given the negative equity and large net losses....
A key strength is the balance sheet, with a debt/equity ratio of 0.0x and a current ratio of 5.08x, indicating a fortress-like liquidity position and no reliance on debt financing. However, the return on equity (ROE) is deeply negative at -57.3%, reflecting significant net losses relative to shareholder equity, which is common for a clinical-stage biotech. Net margin of -597.0% — note this figure may be distorted due to a one-time item or data anomaly —and an unavailable gross margin confirm the company is not yet profitable. Free cash flow is not available, meaning its ability to self-fund operations is unclear, but the low debt and high cash reserves suggest ample runway to invest in research and development without immediate risk of dilution.
EARNINGS QUALITY — While the company has beaten earnings estimates in 4/4 recent quarters, this is not a measure of operational profitability; the underlying business is still generating net losses at a high rate. TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. DEBT / LIQUIDITY — The debt/equity ratio is 0.0x, which is exceptionally low and helpful, but it may reflect an inability to access debt markets rather than a conscious choice, given the negative equity and large net losses.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives